The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Edwards Lifesciences Corp (NYSE: EW) closed at $76.36 in the last session, down -1.50% from day before closing price of $77.52. In other words, the price has decreased by -$1.50 from its previous closing price. On the day, 2.49 million shares were traded. EW stock price reached its highest trading level at $77.37 during the session, while it also had its lowest trading level at $75.275.
Ratios:
We take a closer look at EW’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 70.75. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On January 30, 2025, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $75 to $90.
Wolfe Research Downgraded its Peer Perform to Underperform on January 16, 2025, while the target price for the stock was maintained at $60.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Zovighian Bernard J sold 16,099 shares for $77.21 per share. The transaction valued at 1,243,065 led to the insider holds 9,564 shares of the business.
Zovighian Bernard J sold 967 shares of EW for $74,772 on Jun 03 ’25. The CEO now owns 8,597 shares after completing the transaction at $77.32 per share. On Jun 03 ’25, another insider, Zovighian Bernard J, who serves as the Officer of the company, bought 967 shares for $77.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 45473218560 and an Enterprise Value of 41656573952. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.02, and their Forward P/E ratio for the next fiscal year is 27.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.09 while its Price-to-Book (P/B) ratio in mrq is 4.42. Its current Enterprise Value per Revenue stands at 7.543 whereas that against EBITDA is 24.707.
Stock Price History:
The Beta on a monthly basis for EW is 1.12, which has changed by -0.12229884 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $95.25, while it has fallen to a 52-week low of $58.93. The 50-Day Moving Average of the stock is 2.98%, while the 200-Day Moving Average is calculated to be 7.24%.
Shares Statistics:
According to the various share statistics, EW traded on average about 4.76M shares per day over the past 3-months and 4104140 shares per day over the past 10 days. A total of 586.20M shares are outstanding, with a floating share count of 574.70M. Insiders hold about 2.03% of the company’s shares, while institutions hold 87.86% stake in the company. Shares short for EW as of 1747267200 were 7383664 with a Short Ratio of 1.55, compared to 1744675200 on 7934316. Therefore, it implies a Short% of Shares Outstanding of 7383664 and a Short% of Float of 1.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Edwards Lifesciences Corp (EW) is currently shaped by the ongoing analysis conducted by 26.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.6, with high estimates of $0.65 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.55 and $2.41 for the fiscal current year, implying an average EPS of $2.47. EPS for the following year is $2.75, with 30.0 analysts recommending between $2.93 and $2.61.
Revenue Estimates
According to 26 analysts, the current quarter’s revenue is expected to be $1.49B. It ranges from a high estimate of $1.51B to a low estimate of $1.45B. As of the current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.63BFor the next quarter, 26 analysts are estimating revenue of $1.47B. There is a high estimate of $1.5B for the next quarter, whereas the lowest estimate is $1.44B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $5.98B, while the lowest revenue estimate was $5.77B, resulting in an average revenue estimate of $5.89B. In the same quarter a year ago, actual revenue was $5.44BBased on 31 analysts’ estimates, the company’s revenue will be $6.45B in the next fiscal year. The high estimate is $6.66B and the low estimate is $6.28B.
